Union Therapeutics strikes million-dollar deal with Chinese partner

The drug orismilast, intended to treat different dermatological disorders, and which Union Therapeutics bought from Leo Pharma last year, is now the basis of an agreement worth millions of US dollars for the Danish biotech company.

Photo: Union Therapeutics / PR

When the drug orismilast comes to China, the biotech company Union Therapeutics, headquartered in Denmark, will collaborate with Innovent Biologics, informs the Danish company in a press release.

The statement reads that the two companies have entered into a strategic collaboration and license agreement with the Chinese company, which gives Innovent Biologics exclusive rights to the research, development and commercialization of orismilast in China, including Hong Kong, Macau and Taiwan. The agreement also means that Chinese patients will be included in any future global studies of the drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs